Skip to main content

Table 1 Baseline characteristics of the short-term constant methylation and methylation increase groups compared to the long-term ART group

From: Longitudinal variation in human immunodeficiency virus long terminal repeat methylation in individuals on suppressive antiretroviral therapy

 

Short-Term ART group

Combined

n = 12

p valuea

Short-Term ART group

Constant methylation

n = 5

p valueb

Short-Term ART group

Methylation increase

n = 7

p valuec

p valued

Long-term ART group

n = 10

Sex (Male/Female)

11:1

 

5:0

 

6:1

  

9:1

Age (years)

39 (33–47)

0.013

41 (38–45)

0.910

34 (31–48)

0.004

< 0.001

45 (39–56)

Nadir CD4+ T cell count (cells/mm3)

71 (7–251)

0.294

128 (12–264)

0.843

13 (4–212)

0.106

0.075

96 (47–234)

Pre-ART pVL (RNA copies/mL)

194,077 (67,293–285,046)

0.077

144,952 (90,736–243,202)

0.174

248219 (59,479–285,552)

0.048

0.205

47,800

(7581–154,809)

Delta CD4+ T cell count at 48 months (cells/mm3)

388 (174–502)

< 0.001

330 (130–412)

0.843

455 (214–580)

0.029

< 0.001

291 (193–341)

Delta CD4 % at 48 months

13 (11–20)

0.163

12 (10–15)

0.190

13 (12–32)

0.023

0.041

11 (6–14.5)

Delta CD8+ T cell count at 48 months (cells/mm3)

172 (− 104, 315)

0.053

102 (− 109, 246)

0.751

202 (− 89, 325)

0.105

0.023

− 85 (− 405, 331)

Delta CD8 % at 48 months

− 15 (− 24, − 5)

0.268

− 13 (− 17, 3)

0.015

− 24 (− 25, − 10)

0.162

< 0.001

− 32 (− 46, − 9)

Delta CD4/CD8 at 48 months

0.40 (0.24–0.80)

0.058

0.33 (0.23–0.35)

0.668

0.53 (0.28–0.84)

0.036

< 0.001

0.35 (0.25–0.55)

Days to undetectable pVL

183 (101–368)

0.287

186 (99–384)

0.551

180 (107–344)

0.771

0.205

148 (95–379)

Third drug in current ART regimen (NNRTIs / PIs)

83% / 17%

0.624

80% / 20%

1

86% / 14%

0.603

1

70% / 30%

Number of ART regimen changes

0 (0–1)

0.027

0 (0–0)

0.003

1 (0–1)

0.102

0.008

1 (0.8–2)

  1. For each variable, median (interquartile range) is shown
  2. ART antiretroviral therapy, pVL plasma viral load, NNRTI non-nucleoside reverse transcriptase inhibitors, PI protease inhibitors. Significant p values (p < 0.05) are shown in italic
  3. aShort-term ART group vs. long-term ART group
  4. bConstant methylation group vs. long-term ART group
  5. cMethylation increase group vs. long-term ART group
  6. dConstant methylation group vs. methylation increase group
Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us